New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
18:05 EDTZTSZoetis could climb 25%, Barron's says
Zoetis (ZTS) isn't subject to the same patent expiration cliff as Pfizer (PFE) and earnings should rise 13% over the next few years, Barron's says in its "Weekday Trader" column. Shares could climb 25%, the paper adds. Reference Link
News For ZTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTZTSJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
May 21, 2015
07:37 EDTZTSPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
07:14 EDTZTSBMO Capital to hold a conference
Subscribe for More Information
May 19, 2015
09:43 EDTZTSFDA proposes rule to collect antimicrobial sales, distribution data by species
Subscribe for More Information
May 15, 2015
17:03 EDTZTSPershing Square gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use